GlassScriptPhysician profile
Waring Trible
NPI 1043206238
$4,853.35
in general payments reported to CMS, 2019-2025
23 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $417 · 2021: $781 · 2022: $752 · 2023: $610 · 2024: $628 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.39 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $552.59 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $426.07 | 2019-2025 | |
| Janssen Biotech, INC. | $349.03 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $344.80 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $156.23 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.18 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $137.55 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $99.49 | 2020-2021 | |
| Celgene Corporation | $96.75 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $96.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $84.84 | 2019-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $80.27 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $66.80 | 2019-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $50.80 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $46.90 | 2024-2025 | Ibsrela |
| Evoke Pharma, INC. | $46.01 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $34.26 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $31.78 | 2022 | |
| Shire North American Group INC | $20.95 | 2019 | |
| Enterra Medical, INC. | $20.59 | 2025 | |
| Allergan, INC. | $18.36 | 2020 | |
| Braintree Laboratories, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waring Trible listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.